Imbed Biosciences announced it has secured a strategic investment from BioLab Holdings Inc. that it expects will expand Imbed’s reach in the U.S. market, with a particular focus on physician office settings, and speed development of its proprietary SAM Antimicrobial Technology platform aimed at reducing wound-care complications.
Imbed, which develops advanced synthetic antimicrobial and tissue regeneration solutions, said the investment will support continued expansion of its product platform and further its goal of helping achieve “zero wound-care complications,” supported by what the company described as a growing body of clinical evidence. The company also positioned itself as having a differentiated presence in the skin substitute market, describing its offering as fully synthetic and antimicrobial.
The investment centers on Imbed’s Microlyte product, which the company says targets chronic wound indications and is engineered to reduce bioburden while supporting cell proliferation during the “scaffolding” phase of healing. BioLab said it views Imbed’s SAM technology as a scalable platform that can simplify care delivery and improve patient outcomes, particularly as adoption grows in physician offices.
Imbed Biosciences is a privately held medical device company focused on wound care innovation through its SAM Antimicrobial Technology, which incorporates multiple therapeutic agents into ultra-thin, biocompatible matrices designed to support skin regeneration across chronic and acute wounds. BioLab Holdings, Inc., based in Phoenix, is a medical manufacturer specializing in wound protection, including products that use human tissue allograft derived from amniotic membrane.
KEY QUOTES
“The strategic investment from BioLab Holdings marks a pivotal moment for Imbed Biosciences, significantly expanding our reach of within the critical U.S. market, especially in the MD Office setting, and empowering us to further advance our technology platform, unique in its ability to integrate multiple therapeutic agents into a one-product solution to address unmet needs in wound care.”
Terry Bromley, Chief Executive Officer, Imbed Biosciences
“At BioLab, we invest in platforms that have the potential to elevate how clinicians approach wound care. Imbed’s SAM technology represents a combination of scientific rigor, practical design, and long-term scalability. We see tremendous opportunity to support its adoption in physician office settings, while helping accelerate solutions that simplify care delivery and improve outcomes for patients.”
Jaime Leija, President and Chief Executive Officer, BioLab Holdings
